The latest version of the Pharmaceutical Price Regulation Scheme agreed by the UK government and drugmakers represents “a missed opportunity for patients, industry and the UK economy”. The drugs giant says that the pricing deal shows “a real and growing disconnect between the government’s stated ambitions, and its actions, in life sciences and in improving patients outcomes”. It adds that the “overriding focus on managing costs and its failure to see medicines as a longer term investment is a short term and damaging approach”.
Help employers find you! Check out all the jobs and post your resume.
